Alain Labelle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alain Labelle has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Luc Jean Boulay
2 shared publicationsA.A. Ledoux
1 shared publication- Andrea Lynn Murphy
College of Pharmacy, Dalhousie University, Halifax, NS, Canada
1 shared publication - Ashok Malla
Department of Psychiatry, McGill University, Montreal, Quebec, Canada
1 shared publication - Ayal Schaffer
Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
1 shared publication - Carlo Carandang
Dalhousie University
1 shared publication
Latest Publications
- 1 April 2017
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 41 (S1) , S151
Intrafamilial Homicide: A Descriptive Study of Fratricide in Quebec
Introduction: Fratricide comprises approximately 2% of all intra-familial homicides. Analyses of national data on fratricide show that adult males are considerably more likely to be offenders and victims or fratricide. A previous study suggested there were two main categories of fratricide: related to alcohol intoxication or associated with mental disorder.Objectives: Present and discuss the results of an original study comprising 28 cases of fratricide.Aims: To provide up-to-date scientific knowledge on fratricide.Method: This is a retrospective study of 28 cases of fratricides, extracted from a sample of over 1000 consecutive cases of coroners’ files of victims of domestic homicide occurring between 1990–2015.Results: Two victims out of three were males, most of adult age. There were only 2 female offenders in the whole sample. A majority of victims were Caucasians while 21% were aboriginals. Most victims were stabbed to death. The murders usually occurred at the residence of the victim. In total, 39% of offenders suffered from a major mental illness; 21% were acutely intoxicated at the time. In victims, 29% were under the influence of alcohol and 18% of offenders were free from mental problems.Conclusion: Our data indicates that fratricides are most often impulsive and lack preparation. The most common method was the opportunistic use of a knife, suggestive of impulsive killing, and this is consistent with the rest of the information including the high rate of alcohol use and intoxication at the time. The study confirmed two main categories of fratricide: impulsive killing in the context of alcohol and dispute and killing associated with psychosis.Disclosure of interest: The authors have not supplied their declaration of competing interest.
- 1 April 2017
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 41 (S1) , S151
Intrafamilial Homicide: A Descriptive Study of Fratricide in Quebec
Introduction: Fratricide comprises approximately 2% of all intra-familial homicides. Analyses of national data on fratricide show that adult males are considerably more likely to be offenders and victims or fratricide. A previous study suggested there were two main categories of fratricide: related to alcohol intoxication or associated with mental disorder.Objectives: Present and discuss the results of an original study comprising 28 cases of fratricide.Aims: To provide up-to-date scientific knowledge on fratricide.Method: This is a retrospective study of 28 cases of fratricides, extracted from a sample of over 1000 consecutive cases of coroners’ files of victims of domestic homicide occurring between 1990–2015.Results: Two victims out of three were males, most of adult age. There were only 2 female offenders in the whole sample. A majority of victims were Caucasians while 21% were aboriginals. Most victims were stabbed to death. The murders usually occurred at the residence of the victim. In total, 39% of offenders suffered from a major mental illness; 21% were acutely intoxicated at the time. In victims, 29% were under the influence of alcohol and 18% of offenders were free from mental problems.Conclusion: Our data indicates that fratricides are most often impulsive and lack preparation. The most common method was the opportunistic use of a knife, suggestive of impulsive killing, and this is consistent with the rest of the information including the high rate of alcohol use and intoxication at the time. The study confirmed two main categories of fratricide: impulsive killing in the context of alcohol and dispute and killing associated with psychosis.Disclosure of interest: The authors have not supplied their declaration of competing interest.
- Open Access
- 1 January 2013
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 12 (1) , 1
Evidence review and clinical guidance for the use of ziprasidone in Canada
While indicated for schizophrenia and acute mania, ziprasidone’s evidence base and use in clinical practice extends beyond these regulatory approvals. We, an invited panel of experts led by a working group of 3, critically examined the evidence and our collective experience regarding the effectiveness, tolerability and safety of ziprasidone across its clinical uses. There was no opportunity for manufacturer input into the content of the review. As anticipated, ziprasidone was found to be effective for its indicated uses, although its utility in mania and mixed states lacked comparative data. Beyond these uses, the available data were either unimpressive or were lacking. An attractive characteristic is its neutral effect on weight thereby providing patients with a non-obesogenic long-term treatment option. Key challenges in practice include the need for dosing on a full stomach and managing its early onset adverse effect of restlessness. Addressing these issues are critical to its long-term success
- 1 January 2013
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 12 (1) , 1
Open AccessEvidence review and clinical guidance for the use of ziprasidone in Canada
While indicated for schizophrenia and acute mania, ziprasidone’s evidence base and use in clinical practice extends beyond these regulatory approvals. We, an invited panel of experts led by a working group of 3, critically examined the evidence and our collective experience regarding the effectiveness, tolerability and safety of ziprasidone across its clinical uses. There was no opportunity for manufacturer input into the content of the review. As anticipated, ziprasidone was found to be effective for its indicated uses, although its utility in mania and mixed states lacked comparative data. Beyond these uses, the available data were either unimpressive or were lacking. An attractive characteristic is its neutral effect on weight thereby providing patients with a non-obesogenic long-term treatment option. Key challenges in practice include the need for dosing on a full stomach and managing its early onset adverse effect of restlessness. Addressing these issues are critical to its long-term success
- 31 December 2006
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 16, S393-393
P.3.b.003 Validation of visuospatial navigation as a measure of episodic memory in schizophrenia
- 31 December 2006
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 16, S393-393
P.3.b.003 Validation of visuospatial navigation as a measure of episodic memory in schizophrenia
- Open Access
- 3 June 2006
- Published by Springer Nature in BMC Genomic Data
- Vol. 7 (1) , 34
Association study of the trinucleotide repeat polymorphism within SMARCA2 and schizophrenia
Brahma (BRM) is a key component of the multisubunit SWI/SNF complex, a complex which uses the energy of ATP hydrolysis to remodel chromatin. BRM contains an N-terminal polyglutamine domain, encoded by a polymorphic trinucleotide (CAA/CAG) repeat, the only known polymorphism in the coding region of the gene (SMARCA2). We have examined the association of this polymorphism with schizophrenia in a family-based and case/control study. SMARCA2 was chosen as a candidate gene because of its specific role in developmental pathways, its high expression level in the brain and some evidence of its association with schizophrenia spectrum disorder from genome-wide linkage analysis. Family-based analysis with 281 complete and incomplete triads showed that there is no significant preferential transmission of any of the alleles to the affected offspring. Also, in the case/control analysis, similar allele and genotype distributions were observed between affected cases (n = 289) and unaffected controls (n = 273) in each of three Caucasian populations studied: French Canadian, Tunisian and other Caucasians of European origin. Results from our family-based and case-control association study suggest that there is no association between the trinucleotide repeat polymorphism within SMARCA2 and schizophrenia.
- 3 June 2006
- Published by Springer Nature in BMC Genomic Data
- Vol. 7 (1) , 34
Open AccessAssociation study of the trinucleotide repeat polymorphism within SMARCA2 and schizophrenia
Brahma (BRM) is a key component of the multisubunit SWI/SNF complex, a complex which uses the energy of ATP hydrolysis to remodel chromatin. BRM contains an N-terminal polyglutamine domain, encoded by a polymorphic trinucleotide (CAA/CAG) repeat, the only known polymorphism in the coding region of the gene (SMARCA2). We have examined the association of this polymorphism with schizophrenia in a family-based and case/control study. SMARCA2 was chosen as a candidate gene because of its specific role in developmental pathways, its high expression level in the brain and some evidence of its association with schizophrenia spectrum disorder from genome-wide linkage analysis. Family-based analysis with 281 complete and incomplete triads showed that there is no significant preferential transmission of any of the alleles to the affected offspring. Also, in the case/control analysis, similar allele and genotype distributions were observed between affected cases (n = 289) and unaffected controls (n = 273) in each of three Caucasian populations studied: French Canadian, Tunisian and other Caucasians of European origin. Results from our family-based and case-control association study suggest that there is no association between the trinucleotide repeat polymorphism within SMARCA2 and schizophrenia.
- 1 December 2002
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 22 (6) , 545-553
Switching Outpatients With Schizophrenia and Related Disorders on Long-Acting Injectable Antipsychotics to Olanzapine: An Open-Label Naturalistic Pilot Study
Little is known about the feasibility of switching patients with schizophrenia from long-acting injectable antipsychotics to oral olanzapine. We completed an open-label 14-week study to assess such a transition. This study included 25 stable outpatients (DSM-IV diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective disorder) who were receiving long-acting injectable antipsychotics. Following a screening visit, patients began treatment with olanzapine 10 mg/day, which was initiated the day of their scheduled injection. Clinical assessments included the Clinical Global Impression—Improvement Scale (CGI-I) and the Positive and Negative Syndrome Scale (PANSS). Patient self-reports of adverse events were monitored and the Extrapyramidal Symptoms Rating Scale completed at each visit. In those completing the trial (N = 18), results revealed that a switch from injectable antipsychotics to olanzapine was associated with significant improvements on the CGI-I, negative symptoms, PANSS total scores, and parkinsonism. In considering the whole sample (last observation carried forward, N = 25), significant improvements on the CGI-I, parkinsonism, and dyskinesia were observed. Finally, those who failed to complete the trial (N = 7) did not change significantly from visit 1 to endpoint on any of the efficacy or safety measures. These results should be considered preliminary and require replication using appropriate control groups.
- 1 December 2002
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 22 (6) , 545-553
Switching Outpatients With Schizophrenia and Related Disorders on Long-Acting Injectable Antipsychotics to Olanzapine: An Open-Label Naturalistic Pilot Study
Little is known about the feasibility of switching patients with schizophrenia from long-acting injectable antipsychotics to oral olanzapine. We completed an open-label 14-week study to assess such a transition. This study included 25 stable outpatients (DSM-IV diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective disorder) who were receiving long-acting injectable antipsychotics. Following a screening visit, patients began treatment with olanzapine 10 mg/day, which was initiated the day of their scheduled injection. Clinical assessments included the Clinical Global Impression—Improvement Scale (CGI-I) and the Positive and Negative Syndrome Scale (PANSS). Patient self-reports of adverse events were monitored and the Extrapyramidal Symptoms Rating Scale completed at each visit. In those completing the trial (N = 18), results revealed that a switch from injectable antipsychotics to olanzapine was associated with significant improvements on the CGI-I, negative symptoms, PANSS total scores, and parkinsonism. In considering the whole sample (last observation carried forward, N = 25), significant improvements on the CGI-I, parkinsonism, and dyskinesia were observed. Finally, those who failed to complete the trial (N = 7) did not change significantly from visit 1 to endpoint on any of the efficacy or safety measures. These results should be considered preliminary and require replication using appropriate control groups.
- Open Access
- 1 November 1999
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 44 (9) , 887-892
Retention Rates in Placebo- and Nonplacebo-Controlled Clinical Trials of Schizophrenia
Objective: To determine if the inclusion of a placebo control in clinical trials of schizophrenia affects retention rates in the first 35 days of inclusion relative to trials that did not have a placebo control. Method: This was a retrospective study of 8 double-blind clinical trials, 5 of which had a placebo control while 3 did not. Using survival analysis, retention rates between the placebo-controlled trials (PCTs) and the nonplacebo-controlled trials (NPCTs) were compared. Screening and percentage improvement on Brief Psychiatric Rating Scale and Positive and Negative Syndrome Scale scores were compared. Results: Significantly more patients were retained in the 35-day period for NPCTs. Also, the PCT group had significantly more psychopathology at screening than did the NPCT group. Conclusions: Differences in retention rates between PCTs and NPCTs cannot be uniquely attributed to placebo itself.
- 1 November 1999
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 44 (9) , 887-892
Open AccessRetention Rates in Placebo- and Nonplacebo-Controlled Clinical Trials of Schizophrenia
Objective: To determine if the inclusion of a placebo control in clinical trials of schizophrenia affects retention rates in the first 35 days of inclusion relative to trials that did not have a placebo control. Method: This was a retrospective study of 8 double-blind clinical trials, 5 of which had a placebo control while 3 did not. Using survival analysis, retention rates between the placebo-controlled trials (PCTs) and the nonplacebo-controlled trials (NPCTs) were compared. Screening and percentage improvement on Brief Psychiatric Rating Scale and Positive and Negative Syndrome Scale scores were compared. Results: Significantly more patients were retained in the 35-day period for NPCTs. Also, the PCT group had significantly more psychopathology at screening than did the NPCT group. Conclusions: Differences in retention rates between PCTs and NPCTs cannot be uniquely attributed to placebo itself.
- 1 April 1991
- Vol. 11 (2) , 149-50
Keratodermia: side effects of lithium.